News | March 19, 2026
Alcon walks away from LENSAR deal after regulatory roadblock
At the center of the collapse is opposition from the Federal Trade Commission
At the center of the collapse is opposition from the Federal Trade Commission
SPARK has extended its influence to an additional 9.47 million students worldwide
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Subscribe To Our Newsletter & Stay Updated
